Adjunctive therapy with laquinimod, an aryl hydrocarbon receptor (AhR) agonist, is under evaluation in ongoing phase II clinical trials in SLE patients with active lupus nephritis. This evidence concerns the gene AHR and systemic lupus erythematosus.